The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of S-1 plus split cisplatin (SSP) in patients with advanced gastric cancer (HGCSG0702): Final report.
Satoshi Yuki
No relevant relationships to disclose
Yoshito Komatsu
Research Funding - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Yakult
Hiraku Fukushima
No relevant relationships to disclose
Takahide Sasaki
No relevant relationships to disclose
Yoshimitsu Kobayashi
No relevant relationships to disclose
Kazuaki Harada
No relevant relationships to disclose
Masayoshi Dazai
No relevant relationships to disclose
Susumu Sogabe
No relevant relationships to disclose
Takuto Miyagishima
No relevant relationships to disclose
Atsushi Ishiguro
No relevant relationships to disclose
Takenori Takahata
No relevant relationships to disclose
Atsushi Sato
Honoraria - Taiho Pharmaceutical
Mineo Kudo
No relevant relationships to disclose
Sosuke Kato
No relevant relationships to disclose
Kanji Kato
No relevant relationships to disclose
Ichiro Iwanaga
No relevant relationships to disclose
Nobuyuki Ehira
No relevant relationships to disclose
Minoru Uebayashi
No relevant relationships to disclose
Yuh Sakata
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Merck; Otsuka; Synergy International; Taiho Pharmaceutical; Yakult